certificate of analysis raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-02-16 and is reviewed periodically as new material appears.
Orthogonal separation methods address impurities that RP-HPLC may not resolve. Size-exclusion chromatography detects aggregates and higher-order species, while ion-exchange chromatography separates charge variants. Capillary electrophoresis can assess charge-to-mass ratios and, in some formats, size-based impurities. Amino acid analysis and nitrogen determination estimate peptide content rather than chromatographic purity. Because each technique has a different selectivity, a complete purity profile usually combines results from more than one method. The choice of method depends on the impurity classes of concern.
Reversed-phase high-performance liquid chromatography (RP-HPLC) is widely used to estimate peptide purity. Separation depends on interactions between peptide residues and a hydrophobic stationary phase, with gradients of water and organic solvent. Ultraviolet detection near 214 nm responds to the peptide backbone and to many related impurities. The resulting chromatogram is often expressed as area percent, which reports the proportion of peak area assigned to the main component. Different columns, gradients, and wavelengths can produce different purity values for the same material.
Mass spectrometry provides complementary information about molecular identity and certain impurities. Electrospray ionization and matrix-assisted laser desorption/ionization are common ionization techniques for peptides. A measured mass close to the expected value supports correct sequence length and modifications, while extra mass signals can reveal truncations, adducts, or incomplete deprotection. Mass spectrometry alone is not a quantitative purity assay, because ionization efficiency varies between compounds. Coupling liquid chromatography to mass spectrometry links retention time with mass and helps assign peaks that ultraviolet detection records.
Orthogonal methods reduce the chance that a single technique misses an impurity. Capillary electrophoresis separates by charge-to-size ratio and can resolve variants that co-elute under one set of HPLC conditions. Amino acid analysis reports composition after hydrolysis and confirms the presence of expected residues. Karl Fischer titration measures water content, while ion chromatography can quantify counterions. No single number captures all aspects of sample quality, so reports often combine several measurements.
Peptide purity testing uses separation methods to estimate the proportion of a sample that corresponds to the target sequence. Reverse-phase high-performance liquid chromatography is the most common technique, separating peptides by hydrophobicity on a nonpolar column. Ultraviolet detection at 214 nm records peptide bonds and aromatic residues. The resulting chromatogram is reported as area percent, which reflects relative absorbance rather than absolute mass. This distinction matters because water, counterions, and residual solvents do not appear in the peptide peak.
Mass spectrometry provides an identity check that complements chromatographic purity. Electrospray ionization or matrix-assisted laser desorption/ionization measures the mass-to-charge ratio of intact peptides. A match to the expected molecular mass supports correct sequence length and terminal groups. Mass accuracy alone does not prove that every peak in a liquid chromatogram is the target peptide. It also does not directly quantify how much water or counterion remains in a lyophilized powder.
| Property | Value | Notes |
|---|---|---|
| Common separation technique | Reversed-phase HPLC | Separates mainly by hydrophobicity; gradient elution is typical. |
| Typical detection wavelength | 214 nm | Peptide bond absorbance; also detects many organic impurities. |
| Identity confirmation method | LC-MS or MALDI-MS | Provides molecular mass; not a stand-alone quantitative purity measure. |
| Aggregate assessment method | Size-exclusion chromatography | Detects dimers, oligomers, and larger species. |
| Content assessment method | Amino acid analysis | Estimates peptide mass fraction after hydrolysis and separation. |
Other methods address specific purity concerns. Amino acid analysis gives compositional data after hydrolysis, while capillary electrophoresis separates by charge-to-mass ratio. Karl Fischer titration measures residual water, and gas chromatography can detect residual solvents. Nuclear magnetic resonance can identify organic impurities but is less sensitive for trace levels. No single test covers all possible impurities, so purity testing usually combines orthogonal methods and reports the conditions used. The choice of methods is guided by the impurity classes of interest.
Reverse-phase high-performance liquid chromatography (RP-HPLC) is widely used to estimate peptide purity. It separates components by hydrophobicity on a column with a water-organic mobile phase. Ultraviolet absorbance at 214 nm or 220 nm detects peptide bonds. The main peak area as a percentage of total peak area gives a purity figure. This figure depends on column, gradient, wavelength, and how peaks are integrated, so it is method-specific rather than absolute.
Mass spectrometry provides complementary information by measuring molecular mass. Electrospray ionization or matrix-assisted laser desorption/ionization can confirm the expected peptide mass and reveal related impurities with different masses. It does not directly quantify all species because ionization efficiency varies. When coupled to liquid chromatography, LC-MS can assign masses to chromatographic peaks. This helps distinguish target peptide from truncation, oxidation, or deletion products. Mass accuracy and resolution determine how confidently a mass can be matched to a proposed structure.
Regulatory and accreditation expectations depend on the peptide's intended use. Research reagents may be tested with in-house methods, while pharmaceutical development follows validated procedures and pharmacopeial chapters where applicable. Method validation commonly examines accuracy, precision, specificity, linearity, range, and limits of detection and quantitation. Laboratories accredited to ISO/IEC 17025 must document competence, equipment calibration, and uncertainty. Comparing purity results across laboratories remains difficult because different columns, gradients, detection wavelengths, and integration rules can change reported values; open questions include how best to standardize impurity identification and reporting for diverse peptide products.
Quality control for peptides places purity testing within a documented system that includes specifications, test methods, and acceptance criteria. A certificate of analysis typically reports appearance, chromatographic purity, mass confirmation, and storage conditions. System suitability checks, blank injections, and reference standards help ensure that an analytical run is valid. Traceability requires records of sample preparation, instrument settings, and data processing. No single purity threshold applies to all peptides or uses, so specifications are set according to the intended application and risk assessment.
Sampling and sample preparation influence measured purity. Peptides are often hygroscopic, so weighing should occur quickly under controlled humidity to avoid water uptake. Complete dissolution in a suitable solvent is necessary before injection; undissolved material can block columns or distort results. Filtration removes particulates but may also remove aggregates if the filter pore size is too small. Impurities can originate from synthesis, cleavage, purification, or storage, and forced degradation under heat, light, oxidation, or pH extremes can help identify degradation pathways.
Analytical quality control compares a stored sample against a baseline profile. Reverse-phase chromatography remains common, but stability studies may also use mass spectrometry to detect oxidation, deamidation, or truncation products. Accelerated aging at elevated temperature can reveal degradation pathways, although extrapolation to room temperature is uncertain. Forced degradation studies expose peptides to heat, light, acid, base, and oxidants to identify likely breakdown products. Documentation should record lot number, storage history, and the exact method used for each measurement.
Handling practices reduce the risk of contamination and degradation. Hygroscopic peptides should be equilibrated to room temperature before opening to prevent condensation on the powder. Weighing and reconstitution in a controlled environment limit exposure to moisture and airborne particles. Aliquotting reconstituted solutions avoids repeated freeze-thaw cycles that can cause aggregation or precipitation. When a purity specification is not met, investigation may consider synthesis byproducts, purification losses, storage conditions, and analytical variability rather than a single cause.
Peptide purity can change during storage, handling, and reconstitution, and lyophilized peptides are generally more stable than solutions because water promotes hydrolysis and aggregation. Residual moisture, oxygen, and trace metals can accelerate degradation even in solid form. Temperature fluctuations during shipping may cause condensation and local moisture uptake. Quality control therefore includes appearance, water content, and analytical testing before and after storage challenges. Peptides containing cysteine, methionine, or tryptophan are especially susceptible to oxidation, while asparagine and glutamine residues can deamidate under neutral or alkaline conditions.
Handling and storage influence measured purity, and peptides can oxidize, deamidate, aggregate, or adsorb to surfaces over time. Lyophilized powders stored at -20 °C or lower are generally more stable than solutions, though some sequences require different conditions. Repeated freeze-thaw cycles can promote aggregation and loss, so testing after storage checks whether purity has changed. Stability-indicating methods compare stressed and unstressed samples to detect degradation pathways. Light exposure and pH can also accelerate modification.
Solid-phase peptide synthesis can produce truncated sequences when coupling reactions fail. Deletion peptides lack one or more internal residues, while truncation peptides end prematurely. Side reactions include aspartimide formation, oxidation of methionine, and aggregation during chain assembly. Crude synthetic peptides therefore contain target peptide plus related impurities, counterions, residual solvents, and water. Purification by preparative chromatography reduces these impurities but does not remove every closely related species, including some that differ by a single amino acid.
=== Zostavax === Zostavax contains live attenuated varicella-zoster virus. It is injected subcutaneously (under the skin) in the upper arm. The live vaccine is produced using the MRC-5 line of fetal cells. This has raised religious and ethical concerns for some potential users, since that cell line was derived from an aborted fetus.
The European Centre for Disease Prevention and Control calculated that in 2015, there were 671,689 infections in the EU and European Economic Area caused by antibiotic-resistant bacteria, resulting in 33,110 deaths. Most were acquired in healthcare settings. In 2019 there were 133,000 deaths caused by AMR.
=== Pneumatic elevator === A pneumatic elevator consists of a cylindrical vertical shaft (typically made of transparent plastic), and a passenger capsule (also transparent) within the shaft which moves vertically by means of differential air pressure above and below. The main advantage that it requires neither a pit below or a loft above the shaft. For ascending operations, a vacuum pump at the top of the elevator shaft creates a low pressure by drawing air from above the capsule while below the greater normal atmospheric pressure is permitted to enter at the lower (ground floor) level below the capsule providing lift. To descend, electronically controlled valves inside the tubular shaft regulate the entry and exit of air within the cylinder lowering the car smoothly by means of programmed operation. In the event of a failure of the vacuum pump or electronically controlled valves, the trapped volume of air below the capsule acts as a cushion that is allowed to slowly escape by means of a mechanical valve, gently returning the capsule to the lowest level.
Low-certainty evidence indicates that it mitigates worsening of peripheral neuropathy and disability from disease progression. Inotersen blocks gene expression of both wild-type and mutant TTR, reducing amyloid precursor. Moderate-certainty evidence suggests that it mitigates worsening of peripheral neuropathy. Long-term efficacy and safety of inotersen use in people with mutant TTR-related amyloidosis is still be evaluated in a phase-III clinical trial as of 2021. Both diflunisal and inotersen may also mitigate declines in quality-of-life, though the evidence for this effect is unclear. For people with cardiac ATTR the effect of inotersen use is inconclusive and requires further investigation. In 2018, inotersen was approved by the European Medicines Agency to treat polyneuropathy in adults with hereditary transthyretin amyloidosis. It has since been approved for use in Canada, the European Union and in the USA. Patisiran functions similarly to inotersen. Moderate-certainty evidence suggests that patisiran mitigates worsening of peripheral neuropathy and disability from disease progression. Additionally, low-certainty evidence suggests that patisiran mitigates decreases in quality-of-life and slightly reduces the rate of adverse events versus placebo. There is no evidence of an effect on mortality rate. A review of early data from use of patisiran in people with variant cardiac ATTR suggests that it may reduce mortality and hospitalization, however this is still being investigated and requires further investigation.
In human anatomy, the vitreous body (from Latin vitreus 'glassy') is the clear gel that fills the space between the lens and the retina of the eye (the vitreous chamber) in humans and other vertebrates. It is often referred to as the vitreous humor (also spelled humour, from Latin meaning 'liquid'), or simply "the vitreous". Vitreous fluid or "liquid vitreous" is the liquid component of the vitreous gel, found after a vitreous detachment. It is not to be confused with the aqueous humor, the other fluid in the eye that is found between the cornea and lens.
Sources: en.wikipedia.org
=== 18th century === In 2009, a handwritten household book authored by a Cornishwoman in 1707 was discovered in a house in Hasfield, Gloucestershire, containing a "Recipe for the Scurvy" amongst other largely medicinal and herbal recipes. The recipe consisted of extracts from various plants mixed with a plentiful supply of orange juice, white wine, or beer. In 1734, Leiden-based physician Johann Bachstrom published a book on scurvy in which he stated, "scurvy is solely owing to a total abstinence from fresh vegetable food, and greens; which is alone the primary cause of the disease", and urged the use of fresh fruit and vegetables as a cure.
Cancers are usually named using -carcinoma, -sarcoma or -blastoma as a suffix, with the Latin or Greek word for the organ or tissue of origin as the root. For example, the most common cancer of the liver parenchyma ("hepato-" = liver), arising from malignant epithelial cells ("carcinoma"), would be called a hepatocarcinoma, while a malignancy arising from primitive liver precursor cells is called a hepatoblastoma. Similarly, a cancer arising from malignant fat cells would be termed a liposarcoma. For some common cancers, the English organ name is used. For example, the most common type of breast cancer is called ductal carcinoma of the breast. Benign tumors (which are not cancers) are usually named using -oma as a suffix with the organ name as the root. For example, a benign tumor of smooth muscle cells is called a leiomyoma (the common name of this frequently occurring benign tumor in the uterus is fibroid). Confusingly, some types of cancer use the -noma suffix, examples including melanoma and seminoma. Some types of cancer are named for the size and shape of the cells under a microscope, such as giant cell carcinoma, spindle cell carcinoma, and small-cell carcinoma.
=== Tolerance and dependence === Dependence typified by a withdrawal syndrome occurs in about one-third of individuals who are treated for longer than four weeks with a benzodiazepine. Higher doses and longer periods of use increase the risk of developing a benzodiazepine dependence. Potent benzodiazepines with a relatively short half-life, such as lorazepam, alprazolam, and triazolam, have the highest risk of causing dependence. If regular treatment is continued for longer than four to six months, dose increases may be necessary to maintain effects, but treatment-resistant symptoms may be benzodiazepine withdrawal symptoms. Due to the development of tolerance to the anticonvulsant effects, benzodiazepines are generally not recommended for long-term use for the management of epilepsy. Increasing the dose may overcome tolerance, but tolerance may then develop to the higher dose and adverse effects may persist and worsen. The mechanism of tolerance to benzodiazepines is complex and involves GABAA receptor downregulation, alterations to subunit configuration of GABAA receptors, uncoupling, and internalization of the benzodiazepine binding site from the GABAA receptor complex as well as changes in gene expression. Coming off long-term lorazepam use may be more realistically achieved by a gradual switch to an equivalent dose of diazepam and a period of stabilization on this, and only then initiating dose reductions.
When journalists investigated this business connection, they also discovered that since the events of the protests in 2021, Urquía Carreño's construction company, SME Edificia, had on three separate occasions been subjected to intense and tedious investigations for alleged misconduct and malpractice by agents of the State Security Unit. It was also discovered that State Security agents told Urquía Carreño that if he complied with their wishes, they would leave his company alone. On February 22, 2024, only 48 hours after the first trial, the Supreme Court of Masonic Justice officially expelled Viñas Alonso from the Grand Lodge of Cuba and from the brotherhood of Freemasonry for a total of seven years. Viñas Alonso was given very short notice and could attend the trial, and Second Chamber President Brindisi Limonta was not informed of the proceedings. The Supreme Court's expulsion decision outcome document was not adorned with any signatures or any official seals. Brindisi Limonta expressed his displeasure that he was not invited to the oral hearing, and noted that this "oral hearing" did not even take place in the courthouse on the tenth floor of the National Masonic Temple, and most likely further violated the separation of powers because it was held in Urquía Carreño's office on the eleventh floor, the same office that was supposed to be under investigation by the police for the initial theft. Later that day, on February 22, Valdés García disbarred Brindisi Limonta as a magistrate of the Supreme Court of Masonic Justice.
Between 60% and 75% also mentioned other factors such as core clerkship grades, perceived commitment to specialty, audition elective/rotation within your department, any failed attempt in USMLE, class ranking/quartile, personal prior knowledge of the applicant, perceived interest in program and passing USMLE Step 2 CS. These factors often come as a surprise to many students in the preclinical years, who often work very hard to get great grades, but do not realize that only 45% of directors cite basic science performance as an important measure. Applicants begin the application process with ERAS regardless of their matching program at the beginning of their fourth and final year in medical school. At this point, students choose specific residency programs to apply for that often specify both specialty and hospital system, sometimes even subtracks (e.g., Internal Medicine Residency Categorical Program at Mass General or San Francisco General Primary Care Track).
Sources: en.wikipedia.org
== Reagents developed == (+/-)-PI Reagent (+/-)-PSI Reagent CBMG or "Palau'chlor" CITU Zinc sulfinate salts Zinc trifluoromethanesulfinate (TFMS), zinc difluoromethanesulfinate (DFMS), zinc trifluoroethanesulfinate (TFES), zinc monofluoromethanesulfinate (MFMS), zinc isopropylsulfinate (IPS), zinc triethyleneglycolsulfinate (TEGS) Sulfonyl hydrazides Listed reagents available through standard chemical suppliers
=== Savart: Sound pitch === The savart is an 18th-century unit for measuring the frequency ratio of two sounds. It is equal to 1⁄1000 of a decade (not to be confused with the time period equal to 10 years). The cent is preferred for musical use.
== SELEX variants and alternative aptamer selection methods == FRELEX was developed in 2016 by NeoVentures Biotechnology Inc to allow the selection of aptamers without immobilizing the target or the oligonucleotide library. Immobilization is a necessary component of SELEX; however, it has the potential to inhibit key epitopes, and thus weaken the likelihood of successful binding, particularly when working with small molecules. FRELEX follows a similar overall methodology to SELEX; however, instead of immobilizing the target, the researcher introduces a series of random and blocker oligonucleotides to an immobilization field before introduction to the target. This allows the researcher to better target small molecules that may be lost during partitioning. It also can be used in some circumstances to select an aptamer library without knowing the target. Most modern aptamer selection methods strive to improve the conventional SELEX aptamer search method. Despite the publication of various methods aimed at increasing the affinity and specificity of aptamers, experimental approaches face limitations in the number and variety of sequences that can be examined and selected. Library capacity for SELEX experiments is practically limited to 1015 candidates, whereas, assuming there is a 4-monomeric repertoire from which pools can be created, there are ~1.6 × 1060 unique sequences in sequence space limited to a 100-residue matrix, which is clearly beyond experimental capabilities.
== Collisional reaction interface (CRI) or mini-Collision/Reaction Cell == The proprietary collisional reaction interface (CRI) used in the Bruker ICP-MS Aurora M90 destroys interfering ions. These ions are removed by injecting a collisional gas (He), or a reactive gas (H2), or a mixture of the two, directly into the plasma as it flows through the skimmer cone and/or the sampler cone. Supplying the reactive/collisional gas into the tip of the skimmer cone induces extra collisions and reactions that destroy polyatomic ions in the passing plasma. Fundamentally CRI is a mini- Collision/Reaction Cell installed in front of the parabolic Ion Mirror optics.
This suggests that another factor(s) besides the variant Val58Ile protein's structure is involved in its organ/tissue deposition. A second SNP which is also commonly found in Mexicans occurs at codon 172 of the LECT2 gene. This variant is homozygous for a G nucleotide at this codon position and is associated with an increased incidence of LECT2 amyloidosis. A reason for this association has not yet been proposed. It has been found repeatedly that the mere presence of LECT2 amyloid tissue deposits does not necessarily indicate the presence of LECT2 amyloidosis disease. For example, autopsy studies find that up to 3.1% of Hispanics have these deposits in their kidneys but no history of signs or symptoms that could be attributed to LECT2 amyloidosis. This finding suggests that the LECT2 amyloidosis and its ethnic bias reflect multiple poorly understood factors.
Sources: en.wikipedia.org
RP-HPLC purity is the relative area of the main peptide peak compared with the total integrated peak area. It reflects ultraviolet-absorbing species under one set of separation conditions. It does not identify every impurity or measure biological activity.
Chromatographic conditions such as column chemistry, gradient slope, mobile-phase additives, and detection wavelength affect peak resolution. Sample preparation and integration rules also influence area percent values. Without a shared reference standard and validated method, direct comparisons remain uncertain.
Purity describes the proportion of the main peak among detected components. Peptide content measures the amount of the target peptide in a sample after accounting for counterions, water, and residual salts. A sample can have high chromatographic purity but lower net peptide content.
It measures the relative ultraviolet absorbance area of peptide peaks, usually at 214 nm. It does not directly measure mass, water, counterions, or co-eluting species.